ReviewCureus2025
Stereotactic Radiosurgery for Intramedullary Spinal Cord Metastases: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intramedullary spinal cord metastases (ISCM) represent a rare but increasingly diagnosed cancer dissemination. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiosurgery (FSRS) have emerged as a local treatment option in this context over recent years. This systematic review and meta-analysis aim to assess the safety and effectiveness of SRS/FSRS in ISCM. A systematic literature review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching in PubMed/MEDLINE and Google Scholar databases. Studies were selected based on predefined criteria, with bias risk evaluated using Joanna Briggs Institute (JBI) tools. Relevant data were extracted for subsequent meta-analysis. Descriptive statistics and survival analysis using Kaplan-Meier were performed. Ten studies including 60 patients and 77 ISCM treated with SRS/FSRS were selected. The median age was 50 years, with a female predominance (70%). Breast cancer was the most common metastatic origin (41.7%). Kaplan-Meier analysis in 27 patients showed an estimated overall survival (OS) at 12 months of 35.33% (95% CI 0.18-0.53) and at 24 months of 25.98% (95% CI 0.11-0.44), with a median OS of nine months (95% CI 5.2-14). Local control was achieved in 86.3% at the end of follow-up, with favorable neurological control in 69% of patients and no spinal cord toxicity. The findings of this systematic review and meta-analysis suggest that SRS/FSRS appears to be safe and effective in treating ISCM. However, given the low quality of the included studies, these results should be interpreted with caution. Prospective studies are needed to better define the role of SRS/FSRS and evaluate spinal toxicity in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.